Glucose and corticosterone changes in developing and adult rats following exposure to (±)-3,4-methylendioxymethamphetamine or 5-methoxydiisopropyltryptamine

Neurotoxicology and Teratology

Volumn 32, Issue 2, 2010, Pages 152-157

  Graham, Devon L ^a   Herring, Nicole R ^a   Schaefer, Tori L ^a   Vorhees, Charles V ^a   Williams, Michael T ^a  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

3,4 methylendioxymethamphetamine; 5 methoxydiisopropyltryptamine; Corticosterone; Glucose; Stress hyporesponsive period

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CHLORIDE; CORTICOSTERONE; GLUCOSE; N,N DIISOPROPYL 5 METHOXYTRYPTAMINE;

ADULT ANIMAL; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; COGNITION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEVELOPMENTAL STAGE; DRUG EFFICACY; DRUG EXPOSURE; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; JUVENILE ANIMAL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

5-METHOXYTRYPTAMINE; AGE FACTORS; AGING; ANIMALS; CORTICOSTERONE; FEMALE; GLUCOSE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PITUITARY-ADRENAL SYSTEM; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN AGENTS; UP-REGULATION;

RATTUS;

EID: 77649275451     PISSN: 08920362     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ntt.2009.08.012     Document Type: Article

References (73)

1. Able J.A., Gudelsky G.A., Vorhees C.V., and Williams M.T. 3,4-Methylenedioxymethamphetamine in adult rats produces deficits in path integration and spatial reference memory. Biol. Psychiatry. 59 (2006) 1219-1226
2. Alatrash G., Majhail N.S., and Pile J.C. Rhabdomyolysis after ingestion of "foxy," a hallucinogenic tryptamine derivative. Mayo. Clinic Proc. 81 (2006) 550-551
3. Asensio C., Muzzin P., and Rohner-Jeanrenaud F. Role of glucocorticoids in the physiopathology of excessive fat deposition and insulin resistance. Int. J. Obes. Relat. Metab. Disord. 28 Suppl 4 (2004) S45-52
4. Baumann M.H., Clark R.D., Franken F.H., Rutter J.J., and Rothman R.B. Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges. Neuroscience 152 (2008) 773-784
5. Bayer S.A., Altman J., Russo R.J., and Zhang X. Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology 14 (1993) 83-144
6. Bratt A.M., Kelley S.P., Knowles J.P., Barrett J., Davis K., Davis M., and Mittleman G. Long term modulation of the HPA axis by the hippocampus. Behavioral, biochemical and immunological endpoints in rats exposed to chronic mild stress. Psychoneuroendocrinology 26 (2001) 121-145
7. Broening H.W., Bowyer J.F., and Slikker Jr. W. Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (+/-)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J. Pharmacol. Exp. Ther. 275 (1995) 325-333
8. Broening H.W., Morford L.L., Inman-Wood S.L., Fukumura M., and Vorhees C.V. 3,4-methylenedioxymethamphetamine (ecstasy)-induced learning and memory impairments depend on the age of exposure during early development. J. Neurosci. 21 (2001) 3228-3235
9. Clancy B., Kersh B., Hyde J., Darlington R.B., Anand K.J., and Finlay B.L. Web-based method for translating neurodevelopment from laboratory species to humans. Neuroinformatics 5 (2007) 79-94
10. Cohen M.A., Skelton M.R., Schaefer T.L., Gudelsky G.A., Vorhees C.V., and Williams M.T. Learning and memory after neonatal exposure to 3,4-methylenedioxymethamphetamine (ecstasy) in rats: interaction with exposure in adulthood. Synapse 57 (2005) 148-159
11. Comerci G.D., and Schwebel R. Substance abuse: an overview. Adolesc. Med. 11 (2000) 79-101
12. Commins D.L., Vosmer G., Virus R.M., Woolverton W.L., Schuster C.R., and Seiden L.S. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J. Pharmacol. Exp. Ther. 241 (1987) 338-345
13. Compton D.M., Selinger M.C., Testa E.K., and Larkins K.D. An examination of the effects of 5-Methoxy-n, n-di(ISO)propyltryptamine hydrochloride (Foxy) on cognitive development in rats. Psychol. Rep. 98 (2006) 651-661
14. Connor T.J., McNamara M.G., Finn D., Currid A., O'Malley M., Redmond A.M., Kelly J.P., and Leonard B.E. Acute 3,4-methylenedioxymethamphetamine(MDMA) administration produces a rapid and sustained suppression of immune function in the rat. Immunopharmacology 38 (1998) 253-260
15. Cunha A.R., Aguila M.B., and Mandarim-de-Lacerda C.A. Effects of early postnatal hyperglycaemia on renal cortex maturity, endothelial nitric oxide synthase expression and nephron deficit in mice. Int. J. Exp. Pathol. 89 (2008) 284-291
16. Dallman M.F., Strack A.M., Akana S.F., Bradbury M.J., Hanson E.S., Scribner K.A., and Smith M. Feast and famine: critical role of glucocorticoids with insulin in daily energy flow. Front Neuroendocrinol. 14 (1993) 303-347
17. Darvesh A.S., and Gudelsky G.A. Activation of 5-HT2 receptors induces glycogenolysis in the rat brain. Eur. J. Pharmacol. 464 (2003) 135-140
18. Darvesh A.S., Shankaran M., and Gudelsky G.A. 3,4-Methylenedioxymethamphetamine produces glycogenolysis and increases the extracellular concentration of glucose in the rat brain. J. Pharmacol. Exp. Ther. 301 (2002) 138-144
19. De Kloet E.R., Rosenfeld P., Van Eekelen J.A., Sutanto W., and Levine S. Stress, glucocorticoids and development. Prog. Brain Res. 73 (1988) 101-120
20. Fantegrossi W.E., Harrington A.W., Kiessel C.L., Eckler J.R., Rabin R.A., Winter J.C., Coop A., Rice K.C., and Woods J.H. Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharmacol. Biochem. Behav. 83 (2006) 122-129
21. Farre M., de la Torre R., Mathuna B.O., Roset P.N., Peiro A.M., Torrens M., Ortuno J., Pujadas M., and Cami J. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl) 173 (2004) 364-375
22. Ferrington L., Kirilly E., McBean D.E., Olverman H.J., Bagdy G., and Kelly P.A. Persistent cerebrovascular effects of MDMA and acute responses to the drug. Eur. J. Neurosci. 24 (2006) 509-519
23. Gramsbergen J.B., and Cumming P. Serotonin mediates rapid changes of striatal glucose and lactate metabolism after systemic 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") administration in awake rats. Neurochem. Int. 51 (2007) 8-15
24. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55 (2003) 463-508
25. Green A.R., O'Shea E., and Colado M.I. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur. J. Pharmacol. 500 (2004) 3-13
26. Grob C.S., Poland R.E., Chang L., and Ernst T. Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav. Brain Res. 73 (1996) 103-107
27. Hanson K.L., Luciana M., and Sullwold K. Reward-related decision-making deficits and elevated impulsivity among MDMA and other drug users. Drug Alcohol Depend. 96 (2008) 99-110
28. Ho E., Karimi-Tabesh L., and Koren G. Characteristics of pregnant women who use ecstasy (3, 4-methylenedioxymethamphetamine). Neurotoxicol. Teratol. 23 (2001) 561-567
29. Ikeda A., Sekiguchi K., Fujita K., Yamadera H., and Koga Y. 5-methoxy-N,N-diisopropyltryptamine-induced flashbacks. Am. J. Psychiatry 162 (2005) 815
30. Johnston L.D., O'Malley P.M., Bachman J.G., and Schulenberg J.E. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2008 (NIH Publication No. 09-7401) (2009), National Institute on Drug Abuse, Bethesda, MD
31. Kalechstein A.D., De La Garza Jr. R., Mahoney III J.J., Fantegrossi W.E., and Newton T.F. MDMA use and neurocognition: a meta-analytic review. Psychopharmacology (Berl) 189 (2007) 531-537
32. Kamboj S.S., Chopra K., and Sandhir R. Hyperglycemia-induced alterations in synaptosomal membrane fluidity and activity of membrane bound enzymes: beneficial effect of n-acetylcysteine supplementation. Neuroscience 162 (2009) 349-358
33. Kish S., Fitzmaurice P., Chang L., Furukawa Y., and Tong J. Low striatal serotonin transporter protein in a human polydrug MDMA (ecstasy) user: a case study. J Psychopharmacol (2008) [Electronic publication ahead of print], doi:10.1177/0269881108097724
34. Kuwahara T., Nakakura T., Oda S., Mori M., Uehira T., Okamoto G., Yoshino M., Sasakawa A., Yajima K., Umemoto A., et al. Problems in three Japanese drug users with Human Immunodeficiency Virus infection. J. Med. Invest. 55 (2008) 156-160
35. Mas M., Farre M., de la Torre R., Roset P.N., Ortuno J., Segura J., and Cami J. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J. Pharmacol. Exp. Ther. 290 (1999) 136-145
36. McCann U.D., Szabo Z., Vranesic M., Palermo M., Mathews W.B., Ravert H.T., Dannals R.F., and Ricaurte G.A. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance. Psychopharmacology (Berl) 200 (2008) 439-450
37. McEwen B.S. The neurobiology of stress: from serendipity to clinical relevance. Brain Res. 886 (2000) 172-189
38. Meatherall R., and Sharma P. Foxy, a designer tryptamine hallucinogen. J. Anal. Toxicol. 27 (2003) 313-317
39. Morley K.C., Gallate J.E., Hunt G.E., Mallet P.E., and McGregor S. Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("ecstasy"). Eur. J. Pharmacol. 433 (2001) 91-99
40. Muller A.A. New drugs of abuse update: Foxy Methoxy. J. Emerg. Nurs. 30 (2004) 507-508
41. Nash Jr. J.F., Meltzer H.Y., and Gudelsky G.A. Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 245 (1988) 873-879
42. Obrocki J., Buchert R., Vaterlein O., Thomasius R., Beyer W., and Schiemann T. Ecstasy-long-term effects on the human central nervous system revealed by positron emission tomography. Br. J. Psychiatry 175 (1999) 186-188
43. Ozawa C.R., Ho J.J., Tsai D.J., Ho D.Y., and Sapolsky R.M. Neuroprotective potential of a viral vector system induced by a neurological insult. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 9270-9275
44. Parrott A.C., Lock J., Conner A.C., Kissling C., and Thome J. Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: prospective neuroendocrine and psychobiological changes. Neuropsychobiology 57 (2008) 165-180
45. Quate L., McBean D.E., Ritchie M.M., Olverman H.J., and Kelly P.A. Acute methylenedioxymethamphetamine administration: effects on local cerebral blood flow and glucose utilisation in the Dark Agouti rat. Psychopharmacology (Berl) 173 (2004) 287-295
46. Ricaurte G.A., Forno L.S., Wilson M.A., DeLanney L.E., Irwin I., Molliver M.E., and Langston J.W. (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA 260 (1988) 51-55
47. Rice D., and Barone Jr. S. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ. Health. Perspect. 108 Suppl 3 (2000) 511-533
48. Roiser J.P., Rogers R.D., and Sahakian B.J. Neuropsychological function in ecstasy users: a study controlling for polydrug use. Psychopharmacology (Berl) 189 (2007) 505-516
49. Romeo R.D., Karatsoreos I.N., Ali F.S., and McEwen B.S. The effects of acute stress and pubertal development on metabolic hormones in the rat. Stress 10 (2007) 101-106
50. Rosmond R. Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinology 30 (2005) 1-10
51. Sapolsky R.M., and Meaney M.J. Maturation of the adrenocortical stress response: neuroendocrine control mechanisms and the stress hyporesponsive period. Brain Res. 396 (1986) 64-76
52. Schaefer T.L., Ehrman L.A., Gudelsky G.A., Vorhees C.V., and Williams M.T. Comparison of monoamine and corticosterone levels 24 h following (+)methamphetamine, (+/-)3,4-methylenedioxymethamphetamine, cocaine, (+)fenfluramine or (+/-)methylphenidate administration in the neonatal rat. J. Neurochem. 98 (2006) 1369-1378
53. Schaefer T.L., Skelton M.R., Herring N.R., Gudelsky G.A., Vorhees C.V., and Williams M.T. Short- and long-term effects of (+)-methamphetamine and (+/-)-3,4-methylenedioxymethamphetamine on monoamine and corticosterone levels in the neonatal rat following multiple days of treatment. J. Neurochem. 104 (2008) 1674-1685
54. Schmidt C.J., Black C.K., Abbate G.M., and Taylor V.L. Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res. 529 (1990) 85-90
55. Shulgin A.T., and Carter M.F. N, N-Diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. Commun. Psychopharmacol. 4 (1980) 363-369
56. Skelton M.R., Able J.A., Grace C.E., Herring N.R., Schaefer T.L., Gudelsky G.A., Vorhees C.V., and Williams M.T. (+/-)-3,4-Methylenedioxymethamphetamine treatment in adult rats impairs path integration learning: a comparison of single vs once per week treatment for 5 weeks. Neuropharmacology 204 (2009) 287-297
57. Skelton M.R., Schaefer T.L., Herring N.R., Grace C.E., Vorhees C.V., and Williams M.T. Comparison of the developmental effects of 5-methoxy-N,N-diisopropyltryptamine (Foxy) to (+/-)-3,4-methylenedioxymethamphetamine (ecstasy) in rats. Psychopharmacology (Berl) 204 (2009) 287-297
58. Skelton M.R., Williams M.T., and Vorhees C.V. Treatment with MDMA from P11-20 disrupts spatial learning and path integration learning in adolescent rats but only spatial learning in older rats. Psychopharmacology (Berl) 189 (2006) 307-318
59. Sogawa C., Sogawa N., Tagawa J., Fujino A., Ohyama K., Asanuma M., Funada M., and Kitayama S. 5-Methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor of serotonin transporter. Toxicol. Lett. 170 (2007) 75-82
60. Soto-Montenegro M.L., Vaquero J.J., Arango C., Ricaurte G., Garcia-Barreno P., and Desco M. Effects of MDMA on blood glucose levels and brain glucose metabolism. Eur. J. Nucl. Med. Mol. Imaging 34 (2007) 916-925
61. Tanaka E., Kamata T., Katagi M., Tsuchihashi H., and Honda K. A fatal poisoning with 5-methoxy-N,N-diisopropyltryptamine, Foxy. Forensic. Sci. Int. 163 (2006) 152-154
62. Thomasius R., Zapletalova P., Petersen K., Buchert R., Andresen B., Wartberg L., Nebeling B., and Schmoldt A. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J. Psychopharmacol. 20 (2006) 211-225
63. Drug Enforcement Agency U.S. Notice of intent to place alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I. Microgram. Bull. 36 (2003) 41-43
64. Drug Enforcement Agency U.S. Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule. Fed. Regist. 69 (2004) 58950-58953
65. Vazquez D.M. Stress and the developing limbic-hypothalamic-pituitary-adrenal axis. Psychoneuroendocrinology 23 (1998) 663-700
66. Vorhees C.V., Schaefer T.L., and Williams M.T. Developmental effects of +/-3,4-methylenedioxymethamphetamine on spatial versus path integration learning: effects of dose distribution. Synapse 61 (2007) 488-499
67. Williams M.T., Herring N.R., Schaefer T.L., Skelton M.R., Campbell N.G., Lipton J.W., McCrea A.E., and Vorhees C.V. Alterations in body temperature, corticosterone, and behavior following the administration of 5-methoxy-diisopropyltryptamine ('foxy') to adult rats: a new drug of abuse. Neuropsychopharmacology 32 (2007) 1404-1420
68. Williams M.T., Inman-Wood S.L., Morford L.L., McCrea A.E., Ruttle A.M., Moran M.S., Rock S.L., and Vorhees C.V. Preweaning treatment with methamphetamine induces increases in both corticosterone and ACTH in rats. Neurotoxicol. Teratol. 22 (2000) 751-759
69. Williams M.T., Morford L.L., Wood S.L., Rock S.L., McCrea A.E., Fukumura M., Wallace T.L., Broening H.W., Moran M.S., and Vorhees C.V. Developmental 3,4-methylenedioxymethamphetamine (MDMA) impairs sequential and spatial but not cued learning independent of growth, litter effects or injection stress. Brain Res. 968 (2003) 89-101
70. Williams M.T., Schaefer T.L., Ehrman L.A., Able J.A., Gudelsky G.A., Sah R., and Vorhees C.V. 3,4-Methylenedioxymethamphetamine administration on postnatal day 11 in rats increases pituitary-adrenal output and reduces striatal and hippocampal serotonin without altering SERT activity. Brain Res. 1039 (2005) 97-107
71. Williams M.T., Schaefer T.L., Furay A.R., Ehrman L.A., and Vorhees C.V. Ontogeny of the adrenal response to (+)-methamphetamine in neonatal rats: the effect of prior drug exposure. Stress 9 (2006) 153-163
72. Wilson J.M., McGeorge F., Smolinske S., and Meatherall R. A foxy intoxication. Forensic Sci. Int. 148 (2005) 31-36
73. Wu Z.H., Holzer III C.E., Breitkopf C.R., Grady J.J., and Berenson A.B. Patterns and perceptions of ecstasy use among young, low-income women. Addict. Behav. 31 (2006) 676-685